Hotchkis & Wiley Large Cap Fundamental Value Fund stated the following regarding Elevance Health, Inc. (NYSE:ELV) in its Q4 2024 investor letter: “Elevance Health, Inc. (NYSE:ELV) is a large ...

Analysts have provided Elevance Health with 11 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $476.73, suggesting a potential 41.8% upside.

According to the analyst, Elevance Health, Inc. (NYSE:ELV) operates in 26 states, with Medicaid extended in 18 of them. This expansion covers about 2,055,000 people, or 23% of Elevance's Medicaid ...

ELEVANCE HEALTH is expected to release its quarterly earnings data on Thursday, July 17th before market open, per Finnhub. Analysts are expecting revenue of $48,716,894,722 and earnings of $9.29 ...

ELEVANCE HEALTH posted quarterly earnings results on Tuesday, April 22nd.The company reported earnings of $11.97 per share, beating estimates of $11.50 by $0.47. The company also reported revenue ...

The equity portion of the Abrdn Healthcare Opportunities Fund fell (gross) but outperformed its custom benchmark over the quarter. Click here to read the full commentary.

Elevance, which operates Anthem brand Blue Cross and Blue Shield plans in 14 states and sells an array of government-subsidized benefits, Tuesday said net income fell nearly 3% to $2.18 billion in ...

Shares of Elevance rose 2% to $414 in early trading, while Cigna Group , opens new tab, CVS Health , opens new tab and UnitedHealth were up between 0.7% and 2.4%. On a weekly basis, shares of ...

UPDATED: April 22 at 1 p.m. ET | Elevance Health brought in $2.2 billion in profit for the first quarter of 2025, a figure that surpassed Wall Street's expectations.

Elevance Health on Thursday forecast a first-quarter profit above estimates and maintained its annual profit view, hours after industry bellwether UnitedHealth cut its outlook and sparked a ...

Artisan Select Equity Fund stated the following regarding Elevance Health, Inc. (NYSE:ELV) in its Q4 2024 investor letter: “Elevance Health, Inc. (NYSE:ELV) took a couple of blows this quarter.